Tag: InspireMD

InspireMD Announces Positive Long-Term Safety and Efficacy Data from Ongoing CGuard™ EPS Registries at the Recent 45th Annual Symposium on Vascular and Endovascular Issues, Techniques, Horizons (VEITHsymposium)

TEL AVIV, Israel, Nov. 29, 2018 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced details from several presentations of updated CGuard™ EPS data at the recent VEITHsymposium […]

InspireMD Announces Regulatory and Reimbursement Approval of CGuard™ Embolic Prevention System in Australia

TEL AVIV, Israel, Nov. 28, 2018 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that its novel CGuard™ Embolic Prevention System (EPS) has been granted regulatory approval […]

InspireMD Announces Upcoming Presentations at the 45th Annual Symposium on Vascular and Endovascular Issues, Techniques, Horizons (VEITHsymposium)

TEL AVIV, Israel, Nov. 13, 2018 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that the Company’s CGuard™ Embolic Prevention System will be featured in several podium […]

InspireMD Announces Third Quarter 2018 Financial Results and Provides Corporate Update

TEL AVIV, Israel, Nov. 06, 2018 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced results for the third quarter ending September 30, 2018. Third Quarter 2018 highlights: […]

InspireMD to Report Third Quarter 2018 Financial Results and Provide Business Update on Tuesday, November 6

TEL AVIV, Israel, Oct. 30, 2018 (GLOBE NEWSWIRE) —  InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, announced today that it will host a conference call and webcast on Tuesday, November 6, […]

InspireMD Announces Presentation of Preliminary Cumulative Three-Year CGuard™ EPS Safety and Efficacy Data at the Transcatheter Cardiovascular Therapeutics 2018 Conference

TEL AVIV, Israel, Sept. 27, 2018 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that preliminary cumulative three-year follow-up safety, efficacy and stroke prevention durability data from […]

InspireMD Announces Regulatory Approval of CGuard™ Embolic Prevention System in Mexico

TEL AVIV, Israel, Sept. 24, 2018 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that its novel CGuard™ Embolic Prevention System (EPS) has been granted regulatory approval […]

InspireMD Announces Issuance of Two New U.S. Patents Covering Proprietary MicroNet™ Stent Jacket and Related Drug Eluting Technology

TEL AVIV, Israel, Sept. 17, 2018 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that the United States Patent and Trademark Office (USPTO) has issued US Patents […]

InspireMD to Present at the H.C. Wainwright 20th Annual Global Investment Conference in New York City

TEL AVIV, ISRAEL, Sept. 04, 2018 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced it will be presenting at the H.C. Wainwright 20th Annual […]

InspireMD Reports 94% Increase in CGuard™ EPS Revenues for the Second Quarter of 2018

TEL AVIV, Israel, Aug. 06, 2018 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American:NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced results for the second quarter ending June 30, 2018. Second Quarter 2018 highlights: Revenues […]